A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2005-01-25

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/PNAS.0409071102PMID 15647361PMCID PMC544343
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.

  2005cited by this paper
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

  2004cited by this paper
• Structural and functional analysis of the costimulatory receptor programmed death-1.

  2004cited by this paper
• The roles of the new negative T cell costimulatory pathways in regulating autoimmunity.

  2004cited by this paper
• BTLA: a new inhibitory receptor with a B7-like ligand.

  2003cited by this paper
• Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

  2003cited by this paper
• B7x: A widely expressed B7 family member that inhibits T cell activation

  2003cited by this paper
• BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

  2003cited by this paper
• The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment.

  2003cited by this paper
• Tissue Expression, Protease Specificity, and Kunitz Domain Functions of Hepatocyte Growth Factor Activator Inhibitor-1B (HAI-1B), a New Splice Variant of HAI-1*

  2003cited by this paper
• T‐cell costimulatory pathways in allograft rejection and tolerance

  2003cited by this paper
• Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2.

  2003cited by this paper
• Immunity

  2003cited by this paper
• LIGHT-HVEM signaling and the regulation of T cell-mediated immunity.

  2003cited by this paper
• Structure-Based Analysis of the Herpes Simplex Virus Glycoprotein D Binding Site Present on Herpesvirus Entry Mediator HveA (HVEM)

  2002cited by this paper
• Negative co-receptors on lymphocytes.

  2002cited by this paper
• Targeted Disruption of LIGHT Causes Defects in Costimulatory T Cell Activation and Reveals Cooperation with Lymphotoxin β in Mesenteric Lymph Node Genesis

  2002cited by this paper
• The molecular architecture of the TNF superfamily.

  2002cited by this paper
• Cutting Edge: Selective Impairment of CD8+ T Cell Function in Mice Lacking the TNF Superfamily Member LIGHT

  2002cited by this paper
• The right place at the right time: novel B7 family members regulate effector T cell responses.

  2002cited by this paper
• Structural mechanisms of costimulation

  2002cited by this paper
• The B7–CD28 superfamily

  2002cited by this paper
• Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

  2001cited by this paper
• Herpes simplex virus glycoprotein D bound to the human receptor HveA.

  2001cited by this paper
• Localization of the gD-Binding Region of the Human Herpes Simplex Virus Receptor, HveA

  2001cited by this paper
• The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT.

  2001cited by this paper
• The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function

  2001cited by this paper
• Structural basis for co-stimulation by the human CTLA-4/B7-2 complex

  2001cited by this paper
• The three HveA receptor ligands, gD, LT-α and LIGHT bind to distinct sites on HveA

  2000cited by this paper
• The three HveA receptor ligands, gD, LT-alpha and LIGHT bind to distinct sites on HveA.

  2000cited by this paper
• LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response1

  2000cited by this paper
• Inhibition of Herpes Simplex Virus gD and Lymphotoxin-α Binding to HveA by Peptide Antagonists

  1999cited by this paper
• Inhibition of herpes simplex virus gD and lymphotoxin-alpha binding to HveA by peptide antagonists.

  1999cited by this paper
• LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator.

  1998cited by this paper
• Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry

  1997cited by this paper
• A Newly Identified Member of the Tumor Necrosis Factor Receptor Superfamily with a Wide Tissue Distribution and Involvement in Lymphocyte Activation*

  1997cited by this paper
• Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family.

  1996cited by this paper
• Absence of B7-dependent responses in CD28-deficient mice.

  1994cited by this paper
• Differential T cell costimulatory requirements in CD28-deficient mice.

  1993cited by this paper
• Blood.

  1989cited by this paper
• Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity

  1984cited by this paper

• Efficacy and safety of venanprubart, a BTLA agonist antibody, in patients with active systemic lupus erythematosus

  2026cites this paper
• HVEM-derived peptides as inhibitors of HVEM/LIGHT complex formation.

  2025cites this paper
• BTLA-Expressing Memory B Cells Are Associated with Belimumab-Induced Improvement in Systemic Lupus Erythematosus

  2025cites this paper
• Immune checkpoint blockade for cancer therapy: current progress and perspectives

  2025cites this paper
• PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease

  2025cites this paper
• Negative Immune Checkpoint Inhibitors

  2025cites this paper
• The effect of gD-derived peptides on T cell immune response mediated by BTLA-HVEM protein complex in melanoma patients

  2024cites this paper
• N-Glycan Branching Regulates BTLA Opposite to PD-1 to Limit T Cell Hyperactivity Induced by Branching Deficiency.

  2024cites this paper
• The Role of the CD28 Family Receptors in T-Cell Immunomodulation

  2024cites this paper
• Immune checkpoint inhibitors in infectious disease

  2024cites this paper
• The BTLA-HVEM complex - The future of cancer immunotherapy.

  2024cites this paper
• HVEM in acute lymphocytic leukemia facilitates tumour immune escape by inhibiting CD8+ T cell function

  2024cites this paper
• Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

  2024cites this paper
• A novel disulfidptosis-related immune checkpoint genes signature: forecasting the prognosis of hepatocellular carcinoma

  2023cites this paper
• BTLA-derived peptides as inhibitors of BTLA/HVEM complex formation - design, synthesis and biological evaluation.

  2023cites this paper
• Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy

  2023cites this paper
• BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia

  2023cites this paper
• Immune checkpoint inhibitors for multiple myeloma immunotherapy

  2023cites this paper
• Setting up multicolour TIRF microscopy down to the single molecule level

  2023cites this paper
• Dietary Debaryomyces hansenii promotes skin and skin mucus defensive capacities in a marine fish model

  2023cites this paper
• LCMV induced downregulation of HVEM on antiviral T cells is critical for an efficient effector response

  2022cites this paper
• Targeting the HVEM protein using a fragment of glycoprotein D to inhibit formation of the BTLA/HVEM complex.

  2022cites this paper
• High-throughput virtual screening of small-molecule inhibitors targeting immune cell checkpoints to discover new immunotherapeutics for human diseases

  2022influential citation
• Activation of T cell checkpoint pathways during β‐cell antigen presentation by engineered dendritic cells promotes protection from type 1 diabetes

  2022cites this paper
• Glioma targeted therapy: insight into future of molecular approaches

  2022cites this paper
• The role of the BTLA-HVEM complex in the pathogenesis of autoimmune diseases.

  2022cites this paper
• Activation of T cell checkpoint pathways during β-cell antigen presentation by engineered dendritic cells promotes protection of non-obese diabetic mice from type 1 diabetes

  2021cites this paper
• Switched phenotypes of macrophages during the different stages of Schistosoma japonicum infection influenced the subsequent trends of immune responses.

  2021cites this paper
• Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells

  2021cites this paper
• A Novel Multiplexed Enzyme-Linked Immunosorbent Assay for the Detection of IgG Seroreactivity to Cytomegalovirus (CMV) UL144

  2021influential citation
• Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy

  2021cites this paper
• Roles of BTLA in Immunity and Immune Disorders

  2021cites this paper
• Molecular Features Underlying Shp1/Shp2 Discrimination by Immune Checkpoint Receptors

  2021cites this paper
• PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition

  2021cites this paper
• PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective

  2021cites this paper
• Manipulation of the immune system for cancer defeat: a focus on the T cell inhibitory checkpoint molecules.

  2020cites this paper
• Targeting co-stimulatory molecules in autoimmune disease

  2020cites this paper
• Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding

  2020cites this paper
• Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy

  2020cites this paper
• The synergism of B and T lymphocyte attenuator (BTLA) and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) attenuated acute T-cell mediated rejection and prolonged renal graft survival

  2020cites this paper
• Targeting co-stimulatory molecules in autoimmune disease

  2020cites this paper
• LIGHT deficiency aggravates cisplatin-induced acute kidney injury by upregulating mitochondrial apoptosis.

  2020cites this paper
• Lysosome as the Black Hole for Checkpoint Molecules.

  2020cites this paper
• Herpesvirus Entry Mediator Binding Partners Mediate Immunopathogenesis of Ocular Herpes Simplex Virus 1 Infection

  2020cites this paper
• Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy

  2020cites this paper
• PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2

  2020cites this paper
• BTLA suppress acute rejection via regulating TCR downstream signals and cytokines production in kidney transplantation and prolonged allografts survival

  2019cites this paper
• Co-signal Molecules in T-Cell Activation : Historical Overview and Perspective.

  2019cites this paper
• Signal Transduction Via Co-stimulatory and Co-inhibitory Receptors.

  2019cites this paper
• Engineered Dendritic Cell-Directed Concurrent Activation of Multiple T cell Inhibitory Pathways Induces Robust Immune Tolerance

  2019cites this paper
• A structural model of the immune checkpoint CD160–HVEM complex derived from HDX-mass spectrometry and molecular modeling

  2019cites this paper
• HIV Infection Is Associated With Downregulation of BTLA Expression on Mycobacterium tuberculosis-Specific CD4 T Cells in Active Tuberculosis Disease

  2019influential citation
• CD160 serves as a negative regulator of NKT cells in acute hepatic injury

  2019cites this paper
• BTLA and PD-1 employ distinct phosphatases to differentially repress T cell signaling

  2019cites this paper
• Resveratrol antagonizes thyroid hormone-induced expression of checkpoint and proliferative genes in oral cancer cells

  2019cites this paper
• The Absence of Lymphotoxin-α, a Herpesvirus Entry Mediator (HVEM) Ligand, Affects Herpes Simplex Virus 1 Infection In Vivo Differently than the Absence of Other HVEM Cellular Ligands

  2019cites this paper
• Transcription factors early growth response gene (Egr) 2 and 3 control inflammatory responses of tolerant T cells

  2018cites this paper
• Immunomodulatory Bonds of the Partnership between Dendritic Cells and T Cells.

  2018cites this paper
• Immune Checkpoints as Therapeutic Targets in Autoimmunity

  2018cites this paper
• Quantitative Analysis of Interaction Between CADM1 and Its Binding Cell-Surface Proteins Using Surface Plasmon Resonance Imaging

  2018cites this paper
• Role of B and T Lymphocyte Attenuator in Renal Transplant Recipients with Biopsy-Proven Acute Rejection

  2018cites this paper
• Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients

  2018cites this paper
• Improved Osteogenesis by HVEM-Expressing Allogenic Bone Marrow-Derived Mesenchymal Stem Cells in an Immune Activation Condition and Mouse Femoral Defect Model

  2018cites this paper
• Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis

  2017cites this paper
• The paradoxical changes of membrane and soluble herpes virus entry mediator in hepatocellular carcinoma patients

  2017cites this paper
• Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses

  2017cites this paper
• Immune checkpoint blockade in infectious diseases

  2017cites this paper
• Immunosuppressive Effect of B7-H4 Pathway in a Murine Systemic Lupus Erythematosus Model

  2017cites this paper
• T cell exhaustion: from pathophysiological basics to tumor immunotherapy

  2017cites this paper
• Dichotomous Expression of TNF Superfamily Ligands on Antigen‐Presenting Cells Controls Post‐priming Anti‐viral CD4+ T Cell Immunity

  2017influential citation
• Herpesvirus Entry Mediator and Ocular Herpesvirus Infection: More than Meets the Eye

  2017cites this paper
• The role of lymphotoxin ligand-receptor interactions in regulating epithelial cell fate

  2016cites this paper
• Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses

  2016cites this paper
• Regulatory T Cell Dysfunction Acquiesces to BTLA+ Regulatory B Cells Subsequent to Oral Intervention in Experimental Autoimmune Encephalomyelitis

  2016cites this paper
• The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

  2016cites this paper
• Immune checkpoint inhibitors: a patent review (2010-2015)

  2016cites this paper
• B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity

  2016cites this paper
• Fusion of Glioblastoma Tumor Antigens to Herpes Simplex Virus-1Glycoprotein D Enhances Secondary Adaptive Immune Responses in aDNA Vaccine Strategy

  2015influential citation
• Increased Heterologous Protein Expression in Drosophila S2 Cells for Massive Production of Immune Ligands/Receptors and Structural Analysis of Human HVEM

  2015cites this paper
• Herpes Virus Entry Mediator in Human Corneal Epithelial Cells Modulates the Production of Inflammatory Cytokines in Response to HSV Type 1 Challenge

  2015cites this paper
• Ectopic expression of B and T lymphocyte attenuator in gastric cancer: a potential independent prognostic factor in patients with gastric cancer.

  2015cites this paper
• Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes

  2015cites this paper
• Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

  2015cites this paper
• Herpesvirus entry mediator (HVEM) attenuates signals mediated by the lymphotoxin β receptor (LTβR) in human cells stimulated by the shared ligand LIGHT.

  2014cites this paper
• CD160 isoforms and regulation of CD4 and CD8 T-cell responses

  2014cites this paper
• Therapeutic Blockade of LIGHT Interaction With Herpesvirus Entry Mediator and Lymphotoxin &bgr; Receptor Attenuates In Vivo Cytotoxic Allogeneic Responses

  2014cites this paper
• AAV-sBTLA facilitates HSP70 vaccine-triggered prophylactic antitumor immunity against a murine melanoma pulmonary metastasis model in vivo.

  2014cites this paper
• Baculovirus display for discovery of low‐affinity extracellular receptor‐ligand interactions using protein microarrays (595.2)

  2014cites this paper
• HVEM: An unusual TNF receptor family member important for mucosal innate immune responses to microbes.

  2013cites this paper
• CD160 Activation by Herpesvirus Entry Mediator Augments Inflammatory Cytokine Production and Cytolytic Function by NK Cells

  2013cites this paper
• A study of immunomodulatory genes responses to macrophages of Schistosoma japonicum infection during different stages by microarray analysis.

  2013cites this paper
• Responsesin Modulating Effector CD8 T Cell Functional Dichotomy between OX40 and

  2013cites this paper
• BTLA Interaction with HVEM Expressed on CD8+ T Cells Promotes Survival and Memory Generation in Response to a Bacterial Infection

  2013cites this paper
• CD8 T Cell Memory to a Viral Pathogen Requires Trans Cosignaling between HVEM and BTLA

  2013cites this paper
• Molecular mechanisms of T cell co-stimulation and co-inhibition

  2013cites this paper
• Defining A Regulatory Role For The Hsv Glycoprotein B Membrane Proximal Region In Membrane Association

  2013cites this paper
• Therapeutic Implications of the 4-1BB Costimulatory Pathway on CD8 T Cells during Chronic HIV Infection

  2013cites this paper
• Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity.

  2013cites this paper
• PD-1 is a novel regulator of human B-cell activation.

  2013cites this paper
• B and T lymphocyte attenuator expression in mature B cell lymphomas

  2013cites this paper